Praxis Precision Medicines, Inc.
PRAX
Xếp hạng trong cổ phiếu
#2756
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the... Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Giá cổ phiếu
$245.93
Vốn hóa thị trường
$6.87B
Thay đổi (1 ngày)
1.72%
Thay đổi (1 năm)
29.44%
Quốc gia
US
Giao dịch Praxis Precision Medicines, Inc. (PRAX)
Danh mục
Healthcare
EPS của Praxis Precision Medicines, Inc. (PRAX)
EPS tính đến June 2026 TTM: $-12.95
Theo các báo cáo tài chính mới nhất và giá cổ phiếu của Praxis Precision Medicines, Inc., EPS hiện tại của công ty (TTM) là $-12.95. Vào cuối năm 2023, công ty có EPS là $-18.69, giảm so với EPS năm 2022 là $-69.33.
Lịch sử EPS của Praxis Precision Medicines, Inc. từ 2018 đến 2026
EPS vào cuối mỗi năm
| Năm | EPS | Thay đổi |
|---|---|---|
| 2026 (TTM) | $-12.95 | 26.84% |
| 2024 | $-10.21 | -45.37% |
| 2023 | $-18.69 | -73.04% |
| 2022 | $-69.33 | 17.59% |
| 2021 | $-58.96 | -43.09% |
| 2020 | $-103.61 | -70.25% |
| 2019 | $-348.24 | 13.53% |
| 2018 | $-306.73 | 0.00% |
EPS cho các công ty hoặc đối thủ cạnh tranh tương tự
| Công ty | EPS | Chênh lệch EPS | Quốc gia |
|---|---|---|---|
| $17.32 | -233.75% |
US
|
|
| $-7.98 | -38.38% |
US
|
|
| $-5.29 | -59.15% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -314.21% |
NL
|
